Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
CXCL12 (C-X-C Motif Chemokine Ligand 12)
i
Other names:
CXCL12, C-X-C Motif Chemokine Ligand 12, Stromal Cell-Derived Factor 1, PBSF, Pre-B Cell Growth-Stimulating Factor, Chemokine (C-X-C Motif) Ligand 12, Intercrine Reduced In Hepatomas, SCYB12, TPAR1, SDF1, IRH, C-X-C Motif Chemokine 12, CXCL12, SDF-1a, SDF-1b, TLSF-A, TLSF-B, HSDF-1, SDF1A, SDF1B, SDF-1, TLSF, HIRH
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
6387
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
CXCL12 elevation
Hepatocellular Cancer
CXCL12 elevation
Hepatocellular Cancer
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
T-lymphocyte cell therapy
Sensitive
:
C3
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
T-lymphocyte cell therapy
Sensitive
:
C3
CXCL12 elevation
Renal Cell Carcinoma
CXCL12 elevation
Renal Cell Carcinoma
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
pazopanib
Resistant: C3 – Early Trials
pazopanib
Resistant
:
C3
CXCL12 overexpression
T Cell Non-Hodgkin Lymphoma
CXCL12 overexpression
T Cell Non-Hodgkin Lymphoma
tipifarnib
Sensitive: C3 – Early Trials
tipifarnib
Sensitive
:
C3
tipifarnib
Sensitive: C3 – Early Trials
tipifarnib
Sensitive
:
C3
CXCL12 expression
Peripheral T-cell Lymphoma
CXCL12 expression
Peripheral T-cell Lymphoma
tipifarnib
Sensitive: C3 – Early Trials
tipifarnib
Sensitive
:
C3
tipifarnib
Sensitive: C3 – Early Trials
tipifarnib
Sensitive
:
C3
CXCL12-L
Triple Negative Breast Cancer
CXCL12-L
Triple Negative Breast Cancer
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
CXCL12 expression + PD-L1 underexpression
Non Small Cell Lung Cancer
CXCL12 expression + PD-L1 underexpression
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
CXCL12 expression
Glioblastoma
CXCL12 expression
Glioblastoma
NOX-A12
Sensitive: C3 – Early Trials
NOX-A12
Sensitive
:
C3
NOX-A12
Sensitive: C3 – Early Trials
NOX-A12
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.